

LISTING OF CLAIMS

Claims 1-25 (CANCELED) :

26. (currently amended) A ~~combination~~ composition comprising a combination of an antioxidant agent and a mixed PPAR ligand for the α and γ receptor sub-types, or a selective PPAR ligand for the α receptor sub-type and a selective PPAR ligand for the γ receptor sub-type.

27. (previously presented) The composition of Claim 26, wherein the PPAR ligand is a mixed ligand for the α and γ receptor sub-types.

28. (previously presented) The composition of Claim 26, comprising an antioxidant agent and a selective ligand for the α receptor sub-type and a selective ligand for the γ receptor sub-type.

29. (previously presented) The composition of Claim 26, wherein the selective PPAR ligand for the γ receptor sub-type is rosiglitazone or an addition salt thereof with a pharmaceutically acceptable acid or base.

30. (previously presented) The composition of Claim 26, wherein the antioxidant agent is ubiquinone or coenzyme Q₁₀.

31. (previously presented) A composition comprising a combination of rosiglitazone and coenzyme Q₁₀.

32. (previously presented) A pharmaceutical composition comprising as active ingredient a composition of Claim 26, in combination with one or more pharmaceutically-acceptable excipients.

33. (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of obesity.

5 34. (withdrawn) A method for treating a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of said disorder.

10 35. (withdrawn) A method for treating a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of obesity caused by treatment for type I or II diabetes.

15 36. (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.

20 37. (withdrawn) A method for treating a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.

25 38. (withdrawn) A method for treating a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes comprising the step of

administering to the living animal body, including a human, an amount of a composition of Claim 26 which is effective for alleviation of the condition.

5 **39.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity.

10 **40.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity caused by a therapeutic treatment.

15 **41.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of obesity caused by treatment for type I or II diabetes.

20 **42.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of the
25 condition.

30 **43.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, comprising the step

of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant agent which is effective for alleviation of the condition.

- 5 **44.** (withdrawn) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition comprising one or more PPAR ligands and an antioxidant
10 agent which is effective for alleviation of the condition..